您好,欢迎进入未来科学出版社官网!

用科学铸就未来,用阅读滋养人生

Use science to create the future, and use reading to nourish life

+65 6396 6190

客服服务时间:9:00-18:00

当前位置: 首页 >> 英文期刊 >> Modern General Practice >> 2024 >> 1

The characteristics of serum metabolomics in patients with nonalcoholic fatty liver disease based on gas chromatography-mass spectrometry and its correlation with the severity of the disease

作者:Deng Deming

院校:Hebei Medical University, Hebei Shijiazhuang, 050017

摘要:This study aimed to explore the characteristics of serum metabolomics in patients with non-alcoholic fatty liver disease (NAFLD) and its correlation with the severity of the disease based on gas chromatography - mass spectrometry (GCMS). A total of 200 NAFLD patients and 100 healthy controls were included. Serum samples were collected and analyzed by GC-MS, and the data were processed using multivariate statistical methods such as principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA). The results showed that a total of 50 differential metabolites were identified, including fatty acids such as palmitic acid and oleic acid, amino acids such as glutamine and glycine, and organic acids such as lactate and citrate. The level of palmitic acid was increased while the level of glutamine was decreased in the patient group. Moreover, some of the metabolites were significantly correlated with the severity of the disease. For example, palmitic acid was positively correlated with the severity of NAFLD, while glutamine was negatively correlated. This study indicates that serum metabolomics can effectively distinguish NAFLD patients from healthy individuals, and the characteristic metabolites play a crucial role in the pathogenesis of NAFLD. Furthermore, they have the potential to serve as biomarkers for disease diagnosis and monitoring, providing a basis for a deeper understanding of NAFLD and the development of novel diagnostic and therapeutic strategies.

关键词

Non-alcoholic fatty liver disease; Gas chromatography - mass spectrometry; Serum metabolomics; Disease severity; Biomarkers

全文

PDF

参考

[1] Gitto, S., Federico, A., & Gambino, R. (2018). Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives. Metabolites, 8(2), 30. 

[2] Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84. 

[3] Fatty Liver and Alcoholic Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association; Expert Committee on Fatty Liver Disease, Chinese Medical Doctor Association. (2018). Guidelines for the prevention and treatment of non-alcoholic fatty liver disease (updated version in 2018). Chinese Journal of Hepatology, 26(3), 195–203.

[4] Valenti, L., Alisi, A., & Nobili, V. (2019). Pharmacological treatment of non-alcoholic fatty liver disease: an update. Expert Opinion on Pharmacotherapy, 20(18), 2183–2193.

+65 6396 6190

微信二维码